Target intelligence / Profile preview

Denatured type I collagen

Molecular classification
Other
01

Overview

Denatured type I collagen refers to the unwound or proteolytically degraded state of the most abundant structural protein in the human extracellular matrix (ECM). While native type I collagen forms a stable triple helix that provides mechanical strength to tissues like skin, bone, and tendons, denaturation occurs during pathological remodeling driven by matrix metalloproteinases (MMPs) or mechanical stress (Hwang et al., 2017, ACS Nano). This structural transition exposes cryptic epitopes—binding sites that are hidden in the native protein—which play critical roles in cell signaling, particularly through interactions with integrins like alpha-v-beta-3 (Xu et al., 2001, J. Cell Biol.). In diseases such as cancer and fibrosis, denatured collagen is a hallmark of the remodeled microenvironment, promoting angiogenesis and tumor invasion (Brooks et al., 1998, Cell). Consequently, it serves as a highly selective target for diagnostic imaging and site-specific drug delivery, using agents like collagen-hybridizing peptides (CHPs) or monoclonal antibodies that distinguish between healthy native tissue and diseased, remodeling tissue (Li & Yu, 2013, Soft Matter). These targeting strategies aim to deliver therapeutic payloads or block the pro-migratory signals provided by the degraded matrix (Bennink et al., 2018, Sci Rep).

Other names
GelatinUnwound type I collagenDegraded type I collagenCryptic collagen epitopes
02

Mechanism of action

Selective binding to exposed cryptic epitopes in denatured collagen to inhibit angiogenesis, block cell-matrix interactions, or deliver therapeutic payloads to remodeling tissues.

03

Biological functions

Other
04

Disease associations

CancerInflammationOther
05

Safety considerations

Off-target binding to physiological remodeling sites (e.g., bone turnover)Immunogenicity of synthetic peptides or monoclonal antibodiesSystemic clearance and distribution challenges
06

Interacting drugs

Collagen-hybridizing peptide (CHP)

3 more in the full profile.

07

Biomarkers

C-terminal telopeptide of type I collagen (CTX-I)N-terminal telopeptide of type I collagen (NTX-I)Carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen (ICTP)

Beyond the preview

Go deeper on Denatured type I collagen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Denatured type I collagen.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call